Clinical Trial Update: A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy [Phase 2]

View source ↗

Summary

A Phase II trial in HR-positive, HER2-negative advanced breast cancer after endocrine therapy evaluates entinostat with or without anlotinib, in combination wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Entinostat (entinostat)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING